Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.

Abstract

Mild cognitive impairment (MCI) refers to cognitive impairment that does not meet the criteria of dementia. A major cause of MCI is Alzheimer’s disease (AD) (1). Treatment of AD in subjects with MCI is important as this may give the opportunity to prevent further cognitive decline. In this paper we will review how subjects with MCI were selected in previous AD trials. We will also discuss how biomarkers may contribute to the selection of subjects with MCI in future AD trials.